Shopping Cart
- Remove All
- Your shopping cart is currently empty
Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $33 | In Stock | |
5 mg | $51 | In Stock | |
10 mg | $81 | In Stock | |
25 mg | $153 | In Stock | |
50 mg | $252 | In Stock | |
100 mg | $342 | In Stock | |
500 mg | $827 | In Stock | |
1 mL x 10 mM (in DMSO) | $67 | In Stock |
Description | Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity. |
In vitro | METHODS: Neuroglioma cells U-87 and neuronal primary cultures were treated with Epirubicin hydrochloride (0.5-100 µM) for 48 h. Cell viability was measured by MTT assay. RESULTS: Epirubicin significantly reduced the viability of rat U-87 cells in a concentration-dependent manner, with an IC50 of 6.3 µM. In contrast to U-87 glioma cells, rat normal neuronal cells were resistant to Epirubicin. [1] METHODS: Human breast cancer cells MDA-MB-231 and SK-BR-3 were treated with Epirubicin hydrochloride (2-3 µM) for 48 h, and apoptosis was detected by Flow cytometry. RESULTS: Epirubicin significantly increased sub-G cells in G2/M block. [2] |
In vivo | METHODS: To test the antitumor activity in vivo, Epirubicin hydrochloride (7 mg/kg) was administered intravenously three times at four-day intervals to BALB/c nu/nu nude mice bearing MDA-MB-231 xenografts. RESULTS: Epirubicin reduced tumor growth by half and resulted in a more than 10% weight loss. the IR value of Epirubicin at 7 mg/kg was 53.3%. [2] |
Cell Research | Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37℃, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded.(Only for Reference) |
Alias | Pharmorubicin, Epirubicin HCl, 4'-Epidoxorubicin hydrochloride, 4'-epidoxorubicin HCl |
Molecular Weight | 579.98 |
Formula | C27H30ClNO11 |
Cas No. | 56390-09-1 |
Smiles | Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO |
Relative Density. | 1.61g/cm3 |
Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 42.86 mg/mL (73.9 mM), Sonication is recommended. ![]() Ethanol: 5.8 mg/mL (10 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 5% DMSO+95% Saline: 2.9 mg/mL (5 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.